FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma

FoxM1: A Master Regulator of Tumor Metastasis

(2011) P. Raychaudhuri et al.   CANCER RESEARCH

A novel mode of FoxM1 regulation: Positive auto-regulatory loop

(2011) Marianna Halasi et al.   CELL CYCLE

Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer

(2011) N. Jin et al.   CLINICAL CANCER RESEARCH

The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway

(2011) Ruixin Liu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Akt Inhibitor MK2206 Synergizes, but Perifosine Antagonizes, the BRAFV600EInhibitor PLX4032 and the MEK1/2 Inhibitor AZD6244 in the Inhibition of Thyroid Cancer Cells

(2011) Ruixin Liu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

FoxM1 and Its Association with Matrix Metalloproteinases (MMP) Signaling Pathway in Papillary Thyroid Carcinoma

(2011) Maqbool Ahmed et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The transcription factor FOXM1 is a cellular target of the natural product thiostrepton

(2011) Nagaratna S. Hegde et al.   Nature Chemistry

Molecular genetics and diagnosis of thyroid cancer

(2011) Yuri E. Nikiforov et al.   Nature Reviews Endocrinology

Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer

(2011) C. Nucera et al.   ONCOLOGIST

p53 negatively regulates expression of FoxM1

(2010) Bulbul Pandit et al.   CELL CYCLE

B-RafV600E and thrombospondin-1 promote thyroid cancer progression

(2010) C. Nucera et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genetic Alterations in the Phosphatidylinositol-3 Kinase/Akt Pathway in Thyroid Cancer

(2010) Mingzhao Xing   THYROID

RETRACTED ARTICLE: FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors

(2009) Aamir Ahmad et al.   BREAST CANCER RESEARCH AND TREATMENT

Identification of Polo-like Kinase 1 as a Potential Therapeutic Target in Anaplastic Thyroid Carcinoma

(2009) T. C. Nappi et al.   CANCER RESEARCH

Oncogenic Kras Requires Simultaneous PI3K Signaling to Induce ERK Activation and Transform Thyroid Epithelial Cells In vivo

(2009) K. A. Miller et al.   CANCER RESEARCH

Critical Role and Regulation of Transcription Factor FoxM1 in Human Gastric Cancer Angiogenesis and Progression

(2009) Q. Li et al.   CANCER RESEARCH

Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA, and AKT1

(2009) J. C. Ricarte-Filho et al.   CANCER RESEARCH

Dual Inhibition of Mitogen-Activated Protein Kinase Kinase and Mammalian Target of Rapamycin in Differentiated and Anaplastic Thyroid Cancer

(2009) Ning Jin et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors

(2009) Motoyasu Saji et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer

(2009) U. B. McGovern et al.   MOLECULAR CANCER THERAPEUTICS

Pro-proliferative FoxM1 is a target of p53-mediated repression

(2009) A M Barsotti et al.   ONCOGENE

Thiazole Antibiotics Target FoxM1 and Induce Apoptosis in Human Cancer Cells

(2009) Uppoor G. Bhat et al.   PLoS One

A Novel Orthotopic Mouse Model of Human Anaplastic Thyroid Carcinoma

(2009) Carmelo Nucera et al.   THYROID

Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies

(2008) Robert C Smallridge et al.   ENDOCRINE-RELATED CANCER

Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification

(2008) Rebecca E. Schweppe et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression

(2008) J. M-M. Kwok et al.   MOLECULAR CANCER THERAPEUTICS

Phosphatidylinositol 3-Kinase/Akt and Ras/Raf-Mitogen-Activated Protein Kinase Pathway Mutations in Anaplastic Thyroid Cancer

(2007) Libero Santarpia et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM